🔎 Trials Near Me

Hjem › Ikke-småcellet lungekreft › Georgia › Atlanta

Kliniske studier for Ikke-småcellet lungekreft i Atlanta, GA

47 studier for Ikke-småcellet lungekreft søker deltakere på steder i og rundt Atlanta (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.

Offisiell studietekst (engelsk)

Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

RekruttererFase 3
  • Northside Hospital, Atlanta
Alder 18 og eldre · Alle kjønn · Oppdatert 5. okt. 2026 · NCT04267848

A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors

RekruttererFase 1
  • Winship Cancer Institute of Emory University, Atlanta
Alder 18 og eldre · Alle kjønn · Oppdatert 2. okt. 2026 · NCT06270706

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

RekruttererFase 1
  • Emory University, Atlanta
Alder 18 og eldre · Alle kjønn · Oppdatert 2. okt. 2026 · NCT06465069

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

RekruttererFase 3
  • Emory University Hospital Midtown, Atlanta
  • Emory University Hospital/Winship Cancer Institute, Atlanta
  • Emory Saint Joseph's Hospital, Atlanta
  • og 1 flere
Alder 18 og eldre · Alle kjønn · Oppdatert 1. okt. 2026 · NCT06498635

A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer

RekruttererFase 2
  • Emory Winship Cancer Institute, Atlanta
Alder 18 og eldre · Alle kjønn · Oppdatert 30. sep. 2026 · NCT07659782

Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC

RekruttererFase 3
  • Winship Cancer Institute of Emory University, Atlanta
Alder 18 og eldre · Alle kjønn · Oppdatert 30. sep. 2026 · NCT06765109

Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

RekruttererFase 3
  • Piedmont Healthcare, Inc, Atlanta
  • Winship Cancer Institute, Atlanta
Alder 18 og eldre · Alle kjønn · Oppdatert 29. sep. 2026 · NCT06881784

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

RekruttererFase 3
  • Piedmont Atlanta Hospital ( Site 4000), Atlanta
  • Emory University School of Medicine-Phase I ( Site 0056), Atlanta
  • Northside Hospital ( Site 0055), Atlanta
Alder 18 og eldre · Alle kjønn · Oppdatert 25. sep. 2026 · NCT06312137

A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)

RekruttererFase 2
  • Emory University Winship Cancer Institute, Atlanta
Alder 18 og eldre · Alle kjønn · Oppdatert 25. sep. 2026 · NCT06667908

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

RekruttererFase 2
  • Grady Health System Correll Pavilion, Atlanta
  • Piedmont Healthcare, Atlanta
  • Piedmont Cancer Institute, Atlanta
  • og 1 flere
Alder 18 og eldre · Alle kjønn · Oppdatert 25. sep. 2026 · NCT06667076

Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

RekruttererFase 2
  • Emory University Hospital Midtown, Atlanta
  • Emory University Hospital/Winship Cancer Institute, Atlanta
  • Emory Saint Joseph's Hospital, Atlanta
Alder 18 og eldre · Alle kjønn · Oppdatert 24. sep. 2026 · NCT03191149

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

RekruttererFase 3
  • Winship Cancer Institute, Atlanta
Alder 18 og eldre · Alle kjønn · Oppdatert 24. sep. 2026 · NCT06890598

Pan-tumor MRD Study

RekruttererObservasjonsstudie
  • Piedmont Cancer Institute, Atlanta
Alder 18 og eldre · Alle kjønn · Oppdatert 24. sep. 2026 · NCT06605404

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

RekruttererFase 3
  • Research Site, Atlanta
  • Research Site, Atlanta
Alder 18 og eldre · Alle kjønn · Oppdatert 23. sep. 2026 · NCT06357533

A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)

RekruttererFase 1
  • Emory Winship Cancer Institute, Atlanta
Alder 18 og eldre · Alle kjønn · Oppdatert 23. sep. 2026 · NCT07140016

Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

RekruttererFase 2/3
  • Piedmont Healthcare, Atlanta
Alder 18 og eldre · Alle kjønn · Oppdatert 22. sep. 2026 · NCT07100080

A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors

RekruttererFase 1/2
  • Winship Cancer Institute at Emory University, Atlanta
Alder 18 og eldre · Alle kjønn · Oppdatert 22. sep. 2026 · NCT07488676

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

RekruttererFase 3
  • Clinical Study Site, Atlanta
Alder 18 og eldre · Alle kjønn · Oppdatert 18. sep. 2026 · NCT06767514

Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations

RekruttererFase 3
  • Piedmont Cancer Institute, Atlanta
Alder 18 og eldre · Alle kjønn · Oppdatert 17. sep. 2026 · NCT07195695

Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer

RekruttererFase 3
  • Piedmont Cancer Institute OneOncology, Atlanta
Alder 18 og eldre · Alle kjønn · Oppdatert 15. sep. 2026 · NCT06899126

FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC

RekruttererFase 1/2
  • Emory University, Atlanta
Alder 18 og eldre · Alle kjønn · Oppdatert 14. sep. 2026 · NCT06303505

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

RekruttererFase 3
  • Emory University School of Medicine- Grady Campus, Atlanta
  • Winship Cancer Institute, Emory University, Atlanta
Alder 18 og eldre · Alle kjønn · Oppdatert 8. sep. 2026 · NCT06119581

A Study of Sofe-M in Participants With Selected Advanced Solid Tumors

RekruttererFase 1
  • Emory University, Atlanta
Alder 18 og eldre · Alle kjønn · Oppdatert 4. sep. 2026 · NCT06400472

Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer

RekruttererFase 2
  • Emory Winship Cancer Institute, Atlanta
Alder 18 og eldre · Alle kjønn · Oppdatert 26. aug. 2026 · NCT07288177

MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors

RekruttererFase 1
  • Emory University School of Medicine, Atlanta
Alder 18 og eldre · Alle kjønn · Oppdatert 24. aug. 2026 · NCT06586515

AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors

RekruttererFase 1
  • Emory University, Atlanta
Alder 18 og eldre · Alle kjønn · Oppdatert 30. jul. 2026 · NCT07094113

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

RekruttererFase 1/2
  • Winship Cancer Institute - Emory University, Atlanta
Alder 18 og eldre · Alle kjønn · Oppdatert 29. jul. 2026 · NCT04198766

Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers

RekruttererFase 1/2
  • Winship Cancer Institute, Emory University, Atlanta
Alder 18 og eldre · Alle kjønn · Oppdatert 21. jul. 2026 · NCT05098132

A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)

RekruttererFase 2
  • Research Site, Atlanta
Alder 18 og eldre · Alle kjønn · Oppdatert 1. jul. 2026 · NCT07098338

Study of XB010 in Subjects With Solid Tumors

RekruttererFase 1
  • Winship Cancer Institute, Atlanta
Alder 18 og eldre · Alle kjønn · Oppdatert 22. jun. 2026 · NCT06545331

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

RekruttererFase 2
  • Northside Hospital, Atlanta
Alder 18 og eldre · Alle kjønn · Oppdatert 3. jun. 2026 · NCT05642572

DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors

RekruttererFase 2
  • USA10-0, Atlanta
Alder 18 og eldre · Alle kjønn · Oppdatert 22. mai 2026 · NCT06953089

A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors

RekruttererFase 1
  • Winship Cancer Institute at Emory University, Atlanta
Alder 18 og eldre · Alle kjønn · Oppdatert 18. mai 2026 · NCT07094204

Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

RekruttererFase 1/2
  • Piedmont Healthcare, Atlanta
Alder 18 og eldre · Alle kjønn · Oppdatert 15. mai 2026 · NCT05379985

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

RekruttererFase 2/3
  • Grady Health System, Atlanta
  • Emory University Hospital Midtown, Atlanta
  • Emory University Hospital/Winship Cancer Institute, Atlanta
  • og 3 flere
Alder 18 og eldre · Alle kjønn · Oppdatert 5. mai 2026 · NCT06616584

A Study of DB-1310 in Advanced/Metastatic Solid Tumors

RekruttererFase 1/2
  • Research Site 111, Atlanta
Alder 18 og eldre · Alle kjønn · Oppdatert 6. apr. 2026 · NCT05785741

MRX-2843 and Osimertinib for the Treatment of Advanced EGFR Mutant Non-small Cell Lung Cancer

RekruttererFase 1
  • Emory University Hospital/Winship Cancer Institute, Atlanta
Alder 18 og eldre · Alle kjønn · Oppdatert 31. mar. 2026 · NCT04762199

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

RekruttererObservasjonsstudie
  • Northside Hospital, Atlanta
Alder 18 og eldre · Alle kjønn · Oppdatert 17. mar. 2026 · NCT06418204

Low-Dose Interleukin-2 and Pembrolizumab for the Treatment of Stage IV Non-Small Cell Lung Cancer

RekruttererTidlig fase 1
  • Emory University/Winship Cancer Institute, Atlanta
Alder 18 og eldre · Alle kjønn · Oppdatert 12. feb. 2026 · NCT05493566

Diclofenac for the Treatment of Patients With Metastatic Non-small Cell Lung Cancer on Single Agent Immunotherapy

RekruttererFase 2
  • Emory University Hospital Midtown, Atlanta
  • Emory University Hospital/Winship Cancer Institute, Atlanta
Alder 18 og eldre · Alle kjønn · Oppdatert 12. feb. 2026 · NCT06731270

GEMINI-NSCLC: NSCLC Biomarker Study

RekruttererObservasjonsstudie
  • Morehouse School of Medicine (MSM), Atlanta
  • Piedmont Healthcare, Atlanta
Alder 18 og eldre · Alle kjønn · Oppdatert 5. feb. 2026 · NCT05236114

A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors

RekruttererFase 1/2
  • Research Site 114, Atlanta
  • Research Site 139, Atlanta
Alder 18 og eldre · Alle kjønn · Oppdatert 21. nov. 2025 · NCT05914116

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

RekruttererObservasjonsstudie
  • Massive Bio SYNERGY-AI site, Atlanta
Alle aldre · Alle kjønn · Oppdatert 28. okt. 2025 · NCT03452774

Ikke-småcellet lungekreft-studier i andre byer

Andre studier i Atlanta

Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.